A Single Centre Experience of Effective Desensitization Strategy for Children with High Anti-HLA Donor-Specific

Vimal Kumar1, Rishab Bharadwaj1, Deepti Sachan2

  • 1Department of Pediatric Hematology, Oncology and Blood & Marrow Transplantation, Dr Rela Institute and Medical Centre, 7, CLC Works Road, Chromepet, Chennai, India.

To assess the incidence of anti-HLA donor-specific antibodies and the effectiveness of desensitization strategy in children who underwent haploidentical HSCT at our hospital. A retrospective review, management and outcomes of children with positive anti-HLA DSA who underwent haploidentical HSCT at our hospital from 2020 to 2022. Three patients with Thalassemia major were treated with 2 cycles of pretransplant immune suppression (PTIS) comprising Fludarabine and Dexamethasone in addition to desensitization. Five out of the 26 children who underwent haploidentical HSCT had positive anti-HLA DSA. Post desensitization, three out of the 5 children engrafted with sustained full donor chimerism, 1 patient developed primary graft rejection, while 1 patient died. It is feasible to desensitize children with high anti-HLA donor specific antibodies undergoing haploidentical HSCT to improve outcomes.